Navigation Links
Treating gum disease improves vascular health in Indigenous Australians: Study
Date:6/26/2014

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

The study findings may be of particular importance to Aboriginal Australians, who in general have poorer oral health and higher rates of cardiovascular disease.

Published in the latest issue of Hypertension, the study reports a significant decline in thickening of the wall of the carotid artery a year after a single session of gum treatment.

"The study shows that non-surgical periodontal therapy significantly reduced the progression of thickening of the carotid artery over a one-year period," says study co-author, University of Sydney vascular disease expert Dr Michael Skilton.

"The magnitude of the reduction in thickening of the carotid artery in the treatment group, relative to the control group, is similar to what has been observed in other clinical trials in high risk populations.

"The effect is comparable to a 30 per cent fall in low-density lipoprotein cholesterol commonly referred to as 'bad' cholesterol which is associated with a decreased risk of heart disease.

"It's also equivalent to the effects of reversing four years of aging, 8 kg/m2 lower body mass index, or 25 mm Hg lower systolic blood pressure."

The study was prompted by conjecture about the causative relationship between periodontal (gum) disease and atherosclerotic vascular disease and is among the first using a randomised trial to investigate a periodontal intervention on atherosclerotic disease.

Periodontal disease is an inflammatory disease affecting the soft and hard structures that support the teeth. In its early stage, the gums become swollen and red due to inflammation, which is the body's natural response to the presence of harmful bacteria.

In the more serious form of periodontal disease (periodontitis), the gums pull away from the tooth and supporting gum tissues are destroyed. Bone can be lost, and the teeth may loosen or eventually fall out.

Atherosclerosis is the most common cause of heart attacks, strokes, and peripheral vascular disease collectively known as 'cardiovascular disease'. It usually causes no symptoms until middle or older age but as narrowing and hardening of the arteries accelerates, they choke blood flow, causing pain and other serious cardiovascular complications.

Despite reducing thickening of the carotid artery, the study found no effect of periodontal therapy on arterial stiffness another pre-clinical marker of atherosclerotic vascular disease and risk factor for cardiovascular disease.

"Future studies may tell us whether a more intensive approach to periodontal therapy, including regular periodontal maintenance schedules, can produce more marked improvements in vascular structure," Dr Skilton says.

"The findings indicate that periodontal therapy has a systemic impact beyond treating gum disease.

"If further studies can confirm our report the treatment of periodontal disease may become reducing means by which to reduce the risk of cardiovascular disease, especially in high risk populations such as Indigenous Australians."


'/>"/>

Contact: Dan Gaffney
daniel.gaffney@sydney.edu.au
61-411-156-015
University of Sydney
Source:Eurekalert

Related medicine news :

1. Methadone programs can be key in educating, treating HCV patients
2. Researchers propose treating prison population to fight US hepatitis C epidemic
3. Extended-release medication offers promise for treating alcohol, opioid dependence
4. Widely used drug no more effective than FDA approved medication in treating epileptic seizures
5. Study unveils new approach to treating brittle bone disease
6. Vibrating capsule shows promising results in treating chronic constipation
7. Treating depression in PD patients: New research
8. CU researchers discover target for treating dengue fever
9. New study confirms benefits of treating heart attack patients with a cheap drug
10. Scientists find potential target for treating mitochondrial disorders
11. Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: